NASDAQ:FLGT

Fulgent Genetics (FLGT) Stock Forecast, Price & News

$38.04

-1.59 (-4.01%)

(As of 06/9/2023 ET)

Compare

Today's Range: $37.92
▼
$39.63
50-Day Range: $28.52
▼
$40.70
52-Week Range: $28.27
▼
$65.17

Volume: 248,471 shs
Average Volume: 232,754 shs
Market Capitalization: $1.13 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $42.33

Fulgent Genetics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 11.3% Upside
$42.33 Price Target
Short Interest: Healthy
4.08% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.67
Upright™ Environmental Score
News Sentiment: 0.32
Based on 11 Articles This Week
Insider Trading: Selling Shares
$154,591 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.23) to ($1.80) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

289th out of 987 stocks

Medical Laboratories Industry

7th out of 22 stocks

2.3

Analyst's Opinion

Consensus Rating
Fulgent Genetics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $42.33, Fulgent Genetics has a forecasted upside of 11.3% from its current price of $38.04.
Amount of Analyst Coverage
Fulgent Genetics has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
4.08% of the float of Fulgent Genetics has been sold short.
Short Interest Ratio / Days to Cover
Fulgent Genetics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Fulgent Genetics has recently increased by 7.32%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Fulgent Genetics does not currently pay a dividend.
Dividend Growth
Fulgent Genetics does not have a long track record of dividend growth.

4.1

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Fulgent Genetics has received a 58.06% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Private genetic testing services", "Private infectious disease diagnostics services", and "Private medical laboratory services" products. See details.
Environmental Sustainability
The Environmental Impact score for Fulgent Genetics is -0.67.

2.4

News and Social Media Coverage

News Sentiment
Fulgent Genetics has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for Fulgent Genetics this week, compared to 3 articles on an average week.
Search Interest
Only 12 people have searched for FLGT on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.
MarketBeat Follows
8 people have added Fulgent Genetics to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Fulgent Genetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $154,591.00 in company stock.
Percentage Held by Insiders
31.76% of the stock of Fulgent Genetics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
43.22% of the stock of Fulgent Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Fulgent Genetics are expected to grow in the coming year, from ($2.23) to ($1.80) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Fulgent Genetics is -42.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Fulgent Genetics is -42.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Fulgent Genetics has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Fulgent Genetics (NASDAQ:FLGT) Stock

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded by Ming Hsieh on May 13, 2016 and is headquartered in El Monte, CA.

Receive FLGT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fulgent Genetics and its competitors with MarketBeat's FREE daily newsletter.

FLGT Stock News Headlines

June 8, 2023 | americanbankingnews.com

Paul Kim Sells 1,403 Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) Stock

June 7, 2023 | americanbankingnews.com

Fulgent Genetics, Inc. (NASDAQ:FLGT) COO Jian Xie Sells 1,433 Shares of Stock

June 10, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

June 7, 2023 | americanbankingnews.com

Fulgent Genetics, Inc. (NASDAQ:FLGT) Insider Hanlin Gao Sells 1,000 Shares

June 6, 2023 | finance.yahoo.com

Got $2,500? This Dirt Cheap Growth Stock Could Be Worth Buying Hand Over Fist

June 5, 2023 | finance.yahoo.com

Fulgent Data at ASCO 2023 Highlights Progress for Its Lead Therapeutic Oncology Candidate, FID-007, in Various Cancers

May 30, 2023 | americanbankingnews.com

Fulgent Genetics, Inc. (NASDAQ:FLGT) Short Interest Up 7.3% in May

May 23, 2023 | finance.yahoo.com

2 Undervalued Stocks to Buy for Potentially Massive Gains in the Next 10 Years

June 10, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

May 23, 2023 | finance.yahoo.com

Better Diversified Biotech Stock: 23andMe vs. Fulgent Genetics

May 21, 2023 | americanbankingnews.com

Fulgent Genetics (NASDAQ:FLGT) Research Coverage Started at StockNews.com

May 19, 2023 | msn.com

Fulgent Genetics Earnings Perspective: Return On Capital Employed

May 18, 2023 | finance.yahoo.com

Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2023 Annual Meeting

May 14, 2023 | msn.com

What To Expect From Fulgent Genetics In 2023

May 10, 2023 | americanbankingnews.com

Fulgent Genetics (NASDAQ:FLGT) Releases FY 2023 Earnings Guidance

May 9, 2023 | americanbankingnews.com

Fulgent Genetics (NASDAQ:FLGT) PT Raised to $37.00

May 8, 2023 | finance.yahoo.com

3 Cash-Rich Biotechs in a Market That's Tough on the Debt Burdened

May 8, 2023 | americanbankingnews.com

Fulgent Genetics (NASDAQ:FLGT) Releases FY23 Earnings Guidance

May 5, 2023 | finance.yahoo.com

Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Tops Revenue Estimates

May 5, 2023 | finance.yahoo.com

Fulgent Reports First Quarter 2023 Financial Results

May 4, 2023 | msn.com

Fulgent Genetics Q1 2023 Earnings Preview

May 4, 2023 | msn.com

Preview: Fulgent Genetics's Earnings

May 4, 2023 | americanbankingnews.com

Fulgent Genetics (FLGT) Scheduled to Post Earnings on Friday

April 20, 2023 | finance.yahoo.com

Fulgent Genetics to Announce First Quarter 2023 Financial Results on Friday May 5, 2023

April 18, 2023 | morningstar.com

Fulgent Genetics Inc FLGT Stock Quote

April 14, 2023 | finance.yahoo.com

Returns Are Gaining Momentum At Fulgent Genetics (NASDAQ:FLGT)

April 12, 2023 | msn.com

Are Medical Stocks Lagging Fulgent Genetics (FLGT) This Year?

See More Headlines

FLGT Price History

30 days | 90 days | 365 days | Advanced Chart

FLGT Company Calendar

Last Earnings: 5/05/2023
Today: 6/09/2023
Next Earnings (Estimated): 8/03/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical laboratories
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:FLGT
CUSIP: N/A
CIK: 1674930
Web: www.fulgentgenetics.com
Phone: (626) 350-0537
Fax: 626-454-1667
Employees: 1,012
Year Founded: 2011

Price Target and Rating

Average Stock Price Forecast: $42.33
High Stock Price Forecast: $45.00
Low Stock Price Forecast: $37.00
Forecasted Upside/Downside: +11.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.89)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $143.40 million
Net Margins: -7.10%
Pretax Margin: -10.69%
Return on Equity: -1.05%
Return on Assets: -0.96%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.09
Quick Ratio: 7.09

Sales & Book Value

Annual Sales: $618.97 million
Price / Sales: 1.83
Cash Flow: $6.26 per share
Price / Cash Flow: 6.08
Book Value: $43.14 per share
Price / Book: 0.88

Miscellaneous

Outstanding Shares: 29,700,000
Free Float: 20,268,000
Market Cap: $1.13 billion
Optionable: Not Optionable
Beta: 1.55

Social Links

Key Executives

Ming Hsieh
Chairman & Chief Executive Officer

James Xie
President & Chief Operating Officer

Paul H. Kim
Chief Financial Officer

Harry Gao
Chief Scientific Officer & Laboratory Director

Lawrence M. Weiss
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

FLGT Stock - Frequently Asked Questions

Should I buy or sell Fulgent Genetics stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FLGT shares.
View FLGT analyst ratings or view top-rated stocks.
What is Fulgent Genetics' stock price forecast for 2023?: 3 brokers have issued 1 year target prices for Fulgent Genetics' shares. Their FLGT share price forecasts range from $37.00 to $45.00. On average, they anticipate the company's stock price to reach $42.33 in the next twelve months. This suggests a possible upside of 11.3% from the stock's current price.
View analysts price targets for FLGT or view top-rated stocks among Wall Street analysts.
How have FLGT shares performed in 2023?: Fulgent Genetics' stock was trading at $29.78 on January 1st, 2023. Since then, FLGT shares have increased by 27.7% and is now trading at $38.04.
View the best growth stocks for 2023 here.
When is Fulgent Genetics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our FLGT earnings forecast.
How were Fulgent Genetics' earnings last quarter?: Fulgent Genetics, Inc. (NASDAQ:FLGT) posted its quarterly earnings results on Friday, May, 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.21. The company earned $66.17 million during the quarter, compared to analysts' expectations of $61.95 million. Fulgent Genetics had a negative trailing twelve-month return on equity of 1.05% and a negative net margin of 7.10%.
What ETFs hold Fulgent Genetics' stock?: ETFs with the largest weight of Fulgent Genetics (NASDAQ:FLGT) stock in their portfolio include Invesco Dynamic Biotechnology & Genome ETF (PBE), ETFMG Treatments Testing and Advancements ETF (GERM), ROBO Global Healthcare Technology and Innovation ETF (HTEC), SPDR S&P Health Care Services ETF (XHS), Janus Henderson Small Cap Growth Alpha ETF (JSML), Global X Genomics & Biotechnology ETF (GNOM), Invesco S&P SmallCap Health Care ETF (PSCH) and WisdomTree U.S. SmallCap Fund (EES).
What guidance has Fulgent Genetics issued on next quarter's earnings?: Fulgent Genetics issued an update on its second quarter 2023 earnings guidance on Sunday, May, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $62.00 million-$62.00 million, compared to the consensus revenue estimate of $60.31 million.
What other stocks do shareholders of Fulgent Genetics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), NeoGenomics (NEO), Invitae (NVTA), Block (SQ), JD.com (JD), Marvell Technology (MRVL), Teladoc Health (TDOC) and Editas Medicine (EDIT).

When did Fulgent Genetics IPO?: (FLGT) raised $60 million in an IPO on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray served as the underwriters for the IPO and Raymond James and BTIG were co-managers.
What is Fulgent Genetics' stock symbol?: Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT."
Who are Fulgent Genetics' major shareholders?: Fulgent Genetics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.28%), Dimensional Fund Advisors LP (2.87%), State Street Corp (2.69%), Geode Capital Management LLC (1.36%), JPMorgan Chase & Co. (1.15%) and American Century Companies Inc. (0.94%). Insiders that own company stock include Hanlin Gao, Jian Xie, John C Bolger, Paul Kim and X Cycle LP Tcv.
View institutional ownership trends.
How do I buy shares of Fulgent Genetics?: Shares of FLGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Fulgent Genetics' stock price today?: One share of FLGT stock can currently be purchased for approximately $38.04.
How much money does Fulgent Genetics make?: Fulgent Genetics (NASDAQ:FLGT) has a market capitalization of $1.13 billion and generates $618.97 million in revenue each year. The company earns $143.40 million in net income (profit) each year or ($0.89) on an earnings per share basis.
How many employees does Fulgent Genetics have?: The company employs 1,012 workers across the globe.
Does Fulgent Genetics have any subsidiaries?: The following companies are subsidiares of Fulgent Genetics: CSI, Cytometry Specialists Inc., FF Gene Biotech, Fulgent Investment Development Limited, Fulgent Therapeutics LLC, and Inform Diagnostics.
Read More
How can I contact Fulgent Genetics?: Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780. The official website for the company is www.fulgentgenetics.com. The company can be reached via phone at (626) 350-0537, via email at nborsje@blueshirtgroup.com, or via fax at 626-454-1667.

This page (NASDAQ:FLGT) was last updated on 6/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial